Exelixis (EXEL) Receivables - Net (2012 - 2026)
Exelixis' (EXEL) quarterly Receivables - Net came in at $328.9 million in Q2 2026, up 16.8% year-on-year from $281.6 million in Q2 2025, and up 14.65% quarter-over-quarter from $286.9 million in Q1 2026.
Exelixis (EXEL) Receivables - Net (2012 - 2026) Analysis & Trends
Exelixis' Receivables - Net history runs 15 years deep, the most recent figure standing at $328.9 million for Q2 2026.
- On a quarterly basis, Receivables - Net rose 16.8% year-over-year to $328.9 million in Q2 2026; TTM through Apr 2026 was $328.9 million, a 16.8% increase from a year earlier, with the FY2026 full-year figure at $286.9 million, up 8.09% from the prior year.
- Receivables - Net climbed to $328.9 million in Q2 2026 per EXEL's latest filing, from $286.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $396.6 million in Q2 2024 and bottomed at $190.6 million in Q2 2022.
- The 5-year median for Receivables - Net is $248.1 million (2023), against an average of $263.5 million.
- Across the five-year window, Receivables - Net soared 70.34% in 2024 and declined 26.28% in 2025, its largest moves.
- Year by year, Receivables - Net stood at $214.8 million in 2022, then increased by 10.53% to $237.4 million in 2023, then climbed by 13.6% to $269.7 million in 2024, then climbed by 14.84% to $309.7 million in 2025, then advanced by 6.21% to $328.9 million in 2026.
- Per Business Quant, the three latest EXEL Receivables - Net figures stand at $328.9 million (Q2 2026), $286.9 million (Q1 2026), and $309.7 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 328.95 Mn |
| Apr 3, 2026 | 328.95 Mn |
| Jan 2, 2026 | 286.92 Mn |
| Jan 2, 2026 | 286.92 Mn |
| Oct 3, 2025 | 309.73 Mn |
| Oct 3, 2025 | 309.73 Mn |
| Jul 4, 2025 | 292.35 Mn |
| Jul 4, 2025 | 292.35 Mn |
| Apr 4, 2025 | 281.64 Mn |
| Apr 4, 2025 | 281.64 Mn |
| Jan 3, 2025 | 265.44 Mn |
| Jan 3, 2025 | 265.44 Mn |
| Sep 27, 2024 | 269.71 Mn |
| Sep 27, 2024 | 269.71 Mn |
| Jun 28, 2024 | 396.58 Mn |
| Jun 28, 2024 | 396.58 Mn |
| Mar 29, 2024 | 240.58 Mn |
| Mar 29, 2024 | 240.58 Mn |
| Dec 29, 2023 | 237.41 Mn |
| Dec 29, 2023 | 237.41 Mn |